Precision Medicine Functional Precision Medicine Using MicroOrganoSpheres for Treatment Response Prediction in Advanced Colorectal Cancer

Rákkutatás · Colorectal cancer · TP53 · KRAS

MOS chemoprediction assay showed high reproducibility (coefficients of variation ≤ 2.5 %). MOS drug sensitivity recapitulated patient response with 83 % accuracy in the full sample cohort and 100 % accuracy when derived from primary tumors.

MicroOrganoSpheres (MOS) are droplet‑encapsulated 3D tumor models that enable high‑throughput functional drug testing in patients with advanced colorectal cancer (CRC). MOS derived from primary and metastatic tumors predicted chemotherapy response with 83 % accuracy across the cohort and 100 % accuracy when derived from primary tumors. Sensitive MOS were associated with longer disease‑free survival (DFS). The assay showed high reproducibility (coefficients of variation ≤ 2.5 %) and preserved intratumoral heterogeneity in vitro.

This study demonstrates that an automated, microfluidic‑based MOS assay can reliably predict individual CRC patients’ response to standard dual‑agent chemotherapy, offering a scalable, functional precision‑medicine platform that could guide treatment decisions and improve outcomes.

Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.

Eredeti forrás

Kapcsolódó jelek